Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Bilateral Breast Carcinoma|HER2-Negative Breast Carcinoma|Localized Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma
Interventions: DRUG: Berzosertib|PROCEDURE: Biospecimen Collection|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy
Sponsor: National Cancer Institute (NCI)